Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional

Study of the Long-Term Safety of Pramlintide in Subjects With Type 1 Diabetes Mellitus

ClinicalTrials.gov ID: NCT00107107

Public ClinicalTrials.gov record NCT00107107. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 10:30 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Open-Label, Extension Study of the Long-Term Safety of Pramlintide in Subjects With Type 1 Diabetes Mellitus Completing Protocol 137-150

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a multicenter, open-label extension study designed to examine the long-term safety of pramlintide treatment in subjects with type 1 diabetes who have successfully completed treatment in the parent study 137-150.

Study identification

NCT ID
NCT00107107
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
AstraZeneca
Industry
Enrollment
190 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 31, 2002
Primary completion
May 31, 2005
Completion
May 31, 2005
Last update posted
Sep 22, 2015

2002 – 2005

United States locations

U.S. sites
25
U.S. states
15
U.S. cities
25
Facility City State ZIP Site status
Research Site Tempe Arizona
Research Site Concord California
Research Site Fresno California
Research Site San Diego California
Research Site San Mateo California
Research Site Santa Barbara California
Research Site Walnut Creek California
Research Site Aventura Florida
Research Site Fort Myers Florida
Research Site New Port Richey Florida
Research Site Tallahassee Florida
Research Site Atlanta Georgia
Research Site Indianapolis Indiana
Research Site Detroit Michigan
Research Site Grand Rapids Michigan
Research Site City of Saint Peters Missouri
Research Site Butte Montana
Research Site Durham North Carolina
Research Site Columbus Ohio
Research Site Portland Oregon
Research Site Camp Hill Pennsylvania
Research Site Nashville Tennessee
Research Site Irving Texas
Research Site San Antonio Texas
Research Site Renton Washington

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00107107, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 22, 2015 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00107107 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →